Core Insights - Bio-Path Holdings, Inc. reported financial results for the year ended December 31, 2024, highlighting advancements in its DNAbilize® platform for cancer and obesity treatments [1][5] - The company emphasized the potential of its proprietary technology to transform treatment paradigms in oncology and obesity, with ongoing clinical studies showing promising results [2] Recent Corporate Highlights - Bio-Path expanded its intellectual property portfolio, holding seven issued patents in the U.S. and 61 in foreign jurisdictions, with protections in 26 countries [4] - An update from the Phase 1/1b clinical trial of BP1002 for refractory/relapsed acute myeloid leukemia indicated meaningful patient responses, progressing to a higher dose cohort [4] Financial Results - The company reported a net loss of $9.9 million, or $4.12 per share, for the year ended December 31, 2024, a decrease from a net loss of $16.1 million, or $33.63 per share, in 2023 [7] - Research and development expenses decreased to $7.3 million from $11.6 million in 2023, while general and administrative expenses increased to $4.7 million from $4.2 million [7][11] - As of December 31, 2024, the company had cash of $1.2 million, up from $1.1 million in 2023, with net cash used in operating activities decreasing to $10.6 million from $11.5 million [11]
Bio-Path Holdings Reports Full Year 2024 Financial Results